Clinical analysis of connective tissue disease patients with mycophenolate mofetil and with Pneumocystis jirovecii pneumonia
10.3760/cma.j.issn.1007-7480.2014.08.007
- VernacularTitle:结缔组织病患者合并肺孢子菌肺炎临床分析
- Author:
Yongfeng ZHANG
;
Yi ZHENG
- Publication Type:Journal Article
- Keywords:
Connective tissue diseases;
Pneumonia,pneumocystis;
Mycopbenolate mofetil
- From:
Chinese Journal of Rheumatology
2014;18(8):534-537
- CountryChina
- Language:Chinese
-
Abstract:
Objective The objective of this study is to describe the clinical features and outcomes of connective tissue disease (CTD) patients with mycophenolate mofetil (MMF) and with Pneumocystis jirovecii pneumonia (PJP).Methods We retrospectively reviewed the characteristics,clinical features,treatment and outcomes of PJP in patients with CTD.The clinical variables were compared between groups using t-test.Results ① A total of 17 cases were reviewed.② Sixteen patients were treated with glucocorticoids(GCs) plus immunosuppressive drugs.Only one patient had GCs without immunosuppressive drugs.Sixteen patients were with PJP,10 (63%) patients had MMF.③ Ten MMF patients and 7 non-MMF patients had absolute lymphocyte counts with the average being (557±170)/` and (926±162)/μl,respectively (t=-4.481,P<0.05).④ Six of 17 patients died during the hospitalization.Five patients of 10 patients with MMF died 1 of 7 patients without MMF died.Fifteen of 17 patients were treated by trimethoprim-sulfamethoxazole (TMP-SMX).Conclusion MMF may be risk factors of PJP in CTD.